The Advisory Committee on Immunization Practices voted 9-5 in favor of a recommendation that says adults 65 and older may receive a single dose of RSV vaccine and that shared-decision making with a healthcare provider should be involved, according to an agency news release. For adults between the ages of 60 and 64, the panel voted 13-1 in favor of the same recommendation. Rochelle Walensky, MD, outgoing CDC director, will make the final decision after the advisory committee’s vote.
During the advisory panel meeting, some members expressed concern over the lack of participants older than 75 included in trials for the vaccines from Pfizer and GSK — a group considered to be at highest risk for severe outcomes from RSV. The drugmakers’ resistance to committing to a firm price was also a concern for some ACIP members.
The FDA approved GSK’s respiratory syncytial virus vaccine intended for adults 60 and older on May 3. In a phase 3 study, the vaccine reduced the risk of developing the disease by 82.6 percent and lowered the risk of developing a severe form of the disease by 94.1 percent. Later that month, Pfizer’s RSV shot for older adults was also approved.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
